"Kymera enters 2026 from a position of exceptional strength, driven by significant progress in the clinic and the consistent execution of our strategy,” said Nello Mainolfi, PhD ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
C26 and C27 skarn Neodymium-praseodymium (NdPr) content represents approximately 15% of Total Rare Earth Oxides (TREO) ...
The US Navy has completed a second demonstration of autonomous flight control software using Kratos BQM-177 target drones, ...
BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback